Drug development targeting the glycogen synthase kinase-3ß(GSK- 3ß)-mediated signal transduction pathway: Role of GSK-3β in adult brain

35Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.

Abstract

Glycogen synthase kinase-3β (GSK-3β) is a constitutively active kinase. Since its activation results in neurofibrillary tangle (NFT) deposits in aged and Alzheimer's disease (AD) brains, GSK-3β may be inhibited under normal conditions but activated under pathological conditions. Given its link to NFT formation, we sought to determine whether GSK-3β exists in the brain as a "pathological time bomb" that promotes disease development. To address this hypothesis, we analyzed GSK-3β heterozygote (GSK+/-) mice, which express GSK-3β at 50% wild-type levels. When tested in the Morris water maze test, GSK+/- mice surprisingly exhibited retrograde amnesia. Further analysis indicated that GSK+/- mice had impaired memory reconsolidation but normal memory consolidation. Therefore, we concluded that GSK-3β activation is required for memory reconsolidation in the adult brain. © 2009 The Japanese Pharmacological Society.

Cite

CITATION STYLE

APA

Takashima, A. (2009). Drug development targeting the glycogen synthase kinase-3ß(GSK- 3ß)-mediated signal transduction pathway: Role of GSK-3β in adult brain. Journal of Pharmacological Sciences. Japanese Pharmacological Society. https://doi.org/10.1254/jphs.08R29FM

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free